251 related articles for article (PubMed ID: 19427768)
1. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
[TBL] [Abstract][Full Text] [Related]
2. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.
Zhang CY; Sun AJ; Zhang SN; Wu CN; Fu MQ; Xia G; Wang KQ; Zou YZ; Ge JB
Ann Med; 2010 May; 42(4):305-15. PubMed ID: 20429797
[TBL] [Abstract][Full Text] [Related]
3. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
Ma J; Yang W; Fang N; Zhu W; Wei M
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.
Tkác I
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S57-62. PubMed ID: 20115934
[TBL] [Abstract][Full Text] [Related]
5. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
Lamanna C; Monami M; Marchionni N; Mannucci E
Diabetes Obes Metab; 2011 Mar; 13(3):221-8. PubMed ID: 21205121
[TBL] [Abstract][Full Text] [Related]
6. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
7. Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
Monami M; Adalsteinsson JE; Desideri CM; Ragghianti B; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):591-8. PubMed ID: 23711419
[TBL] [Abstract][Full Text] [Related]
8. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
9. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
[TBL] [Abstract][Full Text] [Related]
10. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
11. Glycemic targets for patients with type 2 diabetes mellitus.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of cardiovascular disease in people with dysglycemia.
Bianchi C; Miccoli R; Penno G; Del Prato S
Diabetes Care; 2008 Feb; 31 Suppl 2():S208-14. PubMed ID: 18227487
[TBL] [Abstract][Full Text] [Related]
13. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
[TBL] [Abstract][Full Text] [Related]
14. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
Miranda VP; Rodrigues MJ; Gonçalves FR; Nunes JP
Rev Port Cardiol; 2009 Oct; 28(10):1099-119. PubMed ID: 20058777
[TBL] [Abstract][Full Text] [Related]
15. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Allemann S; Diem P; Egger M; Christ ER; Stettler C
Curr Med Res Opin; 2006 Mar; 22(3):617-23. PubMed ID: 16574044
[TBL] [Abstract][Full Text] [Related]
16. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
Leschke M
Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
[TBL] [Abstract][Full Text] [Related]
18. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials.
Pittas AG; Siegel RD; Lau J
Arch Intern Med; 2004 Oct; 164(18):2005-11. PubMed ID: 15477435
[TBL] [Abstract][Full Text] [Related]
19. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
